Isoglycemic intravenous glucose lowers plasma glucagon more robustly than oral glucose in healthy subjects, a phenomenon that is magnified in patients with T2D, potentially due to an enhancement in the factors that limit glucagon suppression during an oral glucose challenge (49). This evidence concerns the gene GCG and type 2 diabetes mellitus.